NASDAQ:FLNA

Cassava Sciences Q2 2025 Earnings Results & Report

Cassava Sciences logo
$0.53 +0.05 (+11.15%)
As of 02:47 PM Eastern

Cassava Sciences reported Q2 2025 earnings on August 14, 2025. The company reported EPS of -$0.18.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Cassava Sciences EPS Results

Actual EPS
-$0.18
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Cassava Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cassava Sciences Q2 2025 Earnings FAQ

Cassava Sciences (NASDAQ:FLNA) reported earnings of -$0.18 per share for Q2 2025. The report was announced on Thursday, August 14, 2025.

Cassava Sciences Earnings Headlines

Cassava Sciences (NASDAQ:FLNA) Stock Sees Heavy Call Option Buying
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Cassava Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cassava Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cassava Sciences and other key companies, straight to your email.

About Cassava Sciences

Cassava Sciences (NASDAQ:FLNA) is a biotechnology company focused on developing treatments and diagnostic tools for Alzheimer’s disease. The company’s Nasdaq ticker is SAVA; FLNA does not correspond to Cassava Sciences.

Its research has included simufilam, an investigational oral drug candidate studied for Alzheimer’s, and SavaDX, a blood-based diagnostic program. These are products under development, not approved treatments or tests.

Founded in 1998 as Pain Therapeutics, the company adopted the Cassava Sciences name in 2018. It is headquartered in Austin, Texas, and has been led by founder and chief executive Remi Barbier.

View Cassava Sciences Profile